SHATTUCK LABS INC (STTK)
US82024L1035 - Common Stock
STTK gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability. STTK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year STTK has reported negative net income.
In the past year STTK has reported a negative cash flow from operations.
In the past 5 years STTK always reported negative net income.
STTK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -58.14%, STTK perfoms like the industry average, outperforming 43.08% of the companies in the same industry.
STTK has a Return On Equity of -66.05%. This is comparable to the rest of the industry: STTK outperforms 57.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.14% | ||
| ROE | -66.05% | ||
| ROIC | N/A |
ROA(3y)-39.81%
ROA(5y)-36.64%
ROE(3y)-44.91%
ROE(5y)-62.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for STTK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STTK has more shares outstanding
STTK has more shares outstanding than it did 5 years ago.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 9.12 indicates that STTK is not in any danger for bankruptcy at the moment.
STTK has a Altman-Z score of 9.12. This is amongst the best in the industry. STTK outperforms 84.79% of its industry peers.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.12 |
ROIC/WACCN/A
WACC9%
2.3 Liquidity
STTK has a Current Ratio of 9.15. This indicates that STTK is financially healthy and has no problem in meeting its short term obligations.
STTK has a Current ratio of 9.15. This is in the better half of the industry: STTK outperforms 76.58% of its industry peers.
A Quick Ratio of 9.15 indicates that STTK has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.15, STTK is doing good in the industry, outperforming 76.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.15 | ||
| Quick Ratio | 9.15 |
3. Growth
3.1 Past
STTK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.81%, which is quite good.
STTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 282.96%.
STTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.62% yearly.
EPS 1Y (TTM)16.81%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.49%
Revenue 1Y (TTM)282.96%
Revenue growth 3Y-44.95%
Revenue growth 5Y-40.62%
Revenue growth Q2Q1758.33%
3.2 Future
STTK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.12% yearly.
STTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 109.00% yearly.
EPS Next Y14.04%
EPS Next 2Y5.87%
EPS Next 3Y0.97%
EPS Next 5Y4.12%
Revenue Next Year-10.17%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for STTK. In the last year negative earnings were reported.
Also next year STTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.87%
EPS Next 3Y0.97%
5. Dividend
5.1 Amount
No dividends for STTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SHATTUCK LABS INC
NASDAQ:STTK (5/16/2024, 7:19:15 PM)
After market: 7.84 0 (0%)7.84
-0.32 (-3.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap372.79M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.14% | ||
| ROE | -66.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.15 | ||
| Quick Ratio | 9.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.81%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)282.96%
Revenue growth 3Y-44.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y